Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act.
about
Outbreak of acute renal failure in Panama in 2006: a case-control studyDrug safety: The concept, inception and its importance in patients' healthThe Nuremberg Code subverts human health and safety by requiring animal modelingChildren with multiple sclerosis should not become therapeutic hostagesA conceptual framework for evaluating outpatient electronic prescribing systems based on their functional capabilities.The need for better data about counterfeit drugs in developing countries: a proposed standard research methodology tested in Chennai, India.Osmol gap method for the detection of diethylene glycol in human serum.Substandard drugs: a potential crisis for public health.Translational toxicology and the work of the predictive safety testing consortium.Clinical trials in childrenClinical Features of Reported Ethylene Glycol Exposures in the United StatesThe contributions of the European Medicines Agency and its pediatric committee to the fight against childhood leukemiaMonitoring gene changes during antiepileptic drug therapy to widen the safety window and reduce pharmacoresistance.Adulteration of drugs and foods: compendial approaches to lowering risk.Hippocratic oath and conversion of ethico-regulatory aspects onto doctors as a physician, private individual and a clinical investigator.Delayed neurological sequelae from ethylene glycol, diethylene glycol and methanol poisonings.Historical perspective on the use of animal bioassays to predict carcinogenicity: evolution in design and recognition of utility.Governmental oversight of prescribing medications: history of the US Food and Drug Administration and prescriptive authority.The value of juvenile animal studies: a pediatric clinical perspective.The management of subacute bacterial endocarditis superimposed on rheumatic heart disease in the immediate pre-penicillin era: the case of Pasquale Imperato.Vehicle selection for nonclinical oral safety studies.Risks and benefits of phase 1 clinical trial participation.Pathway Based Toxicology and Fit-for-Purpose Assays.Inhibition of metabolism of diethylene glycol prevents target organ toxicity in rats.Busulfan in children: impact of development on dose-exposure-response relationship?How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications.It's happening again--another diethylene glycol mass poisoning.Therapeutic disasters that hastened safety testing of new drugs.Commentary on Wagener et al. (2012): laissez-faire regulation: turning back the clock on the Food and Drug Administration and public health.Off-label and unlicensed paediatric prescribing in a community setting: a prospective longitudinal cohort study in Malta.Toxicology of Specific Substances
P2860
Q24646767-F041DE8F-39FD-413B-91EC-373117323902Q26744021-D95B8633-D33E-4F26-B1E3-B7D296BC0BADQ26866469-C3E8BB82-33B6-4DA0-93EF-8FF2460B71A1Q28077271-C174F6D9-3618-4374-80B8-ED278659CB7FQ30449486-A744FBD5-9DFA-4B97-B3B8-4526FEB1E743Q33950863-1DA01AC0-2E89-4EB1-A4B2-4B2271341E28Q34031945-063DDF74-32B3-426F-B2A4-2370FC0FE331Q34065256-569B5253-D1FC-48F3-AF9D-5F3315AAB9F7Q34926489-C7943C7E-4C88-49FD-B607-28B77FBC307FQ35135928-87DBBCCF-E5EB-4549-929D-7783D4DB55DEQ35840885-4A3290D3-7E02-49F3-AFDB-FF65EF61630FQ36267151-7D8E82DD-8BA3-4FE4-8619-762491347F77Q36742742-B8BB7395-6F9A-42BA-9E8F-D1961D7E61E8Q37157251-863B4727-EB0E-4CF3-A071-B5AC2E5B0A67Q37413911-97F1CBD0-3A9F-4A53-BE89-394839A52392Q37824703-33396F58-E7E9-4D58-AF24-F62DDA4DA88FQ37857848-B11935D4-C0EB-4FDF-BBBE-06D758B1C811Q37871037-3DF8CEE6-3FA8-4450-8BB7-D46F8FAB020DQ37877215-517F19D9-A885-4F37-A279-0889150F8CA1Q38053863-114CE492-95F1-4298-BF0F-61C9704B5386Q38145410-42C8EE80-FD43-4815-AA75-B1EC7D6A1A6CQ38222465-9E6EB063-08E3-4447-A76A-447BE0F739D8Q39348556-9C267831-4CAC-430D-AC2F-2A168427A5C9Q43041981-EFD2AB4E-8959-489D-B931-2EC5645E52F7Q43232307-9EE33F71-FF7E-4579-9B95-0D81925005ADQ45911336-E5C24224-0443-4D4D-9842-3D7F3CEE4CCFQ46473455-282DE19F-E4E2-43CC-B002-AE22926A117AQ47569741-1651FE9E-C629-4571-BD45-7A66DE919EFAQ49184593-6E60A371-4258-4150-950B-47B42E1A805DQ54312608-FC97ECA5-A5C2-4CBD-8A73-C1B99268E878Q57986556-6426A7FD-EEFF-4D59-A497-661E7F17B09E
P2860
Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act.
description
1995 nî lūn-bûn
@nan
1995 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի մարտին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act.
@ast
Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act.
@en
Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act.
@nl
type
label
Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act.
@ast
Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act.
@en
Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act.
@nl
prefLabel
Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act.
@ast
Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act.
@en
Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act.
@nl
P1476
Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act.
@en
P2093
P304
P356
10.7326/0003-4819-122-6-199503150-00009
P407
P577
1995-03-01T00:00:00Z